Survival and stability of patients with urothelial cancer and spinal bone metastases after palliative radiotherapy

1Bianchi M, Roghmann F, Becker A, Sukumar S, Briganti A, Menon M, et al. Age-stratified distribution of metastatic sites in bladder cancer: A population-based analysis. Can Urol Assoc J 2014; 8: E148-58. 10.5489/cuaj.787BianchiMRoghmannFBeckerASukumarSBrigantiAMenonM Age-stratified distribution of metastatic sites in bladder cancer: A population-based analysis Can Urol Assoc J 2014 8 E14858 10.5489/cuaj.787Open DOISearch in Google Scholar

2Lutz S, Berk L, Chang E, Chow E, Hahn C, Hoskin P, et al. Palliative radiotherapy for bone metastases: an ASTRO evidence-based guideline. Int J Radiat Oncol Biol Phys 2011; 79: 965-76. 10.1016/j.ijrobp.2010.11.026LutzSBerkLChangEChowEHahnCHoskinP Palliative radiotherapy for bone metastases: an ASTRO evidence-based guideline Int J Radiat Oncol Biol Phys 2011 79 96576 10.1016/j.ijrobp.2010.11.026Open DOISearch in Google Scholar

3Taneichi H, Kaneda K, Takeda N, Abumi K, Satoh S. Risk factors and probability of vertebral body collapse in metastases of the thoracic and lumbar spine. Spine (Phila Pa 1976) 1997; 22: 239-45.TaneichiHKanedaKTakedaNAbumiKSatohS. Risk factors and probability of vertebral body collapse in metastases of the thoracic and lumbar spine Spine (Phila Pa 1976) 1997 22 2394510.1097/00007632-199702010-00002Search in Google Scholar

4Foerster R, Habermehl D, Bruckner T, Bostel T, Schlampp I, Welzel T, et al. Spinal bone metastases in gynecologic malignancies: a retrospective analysis of stability, prognostic factors and survival. Radiat Oncol 2014; 9: 194. 10.1186/1748-717X-9-194FoersterRHabermehlDBrucknerTBostelTSchlamppIWelzelT Spinal bone metastases in gynecologic malignancies: a retrospective analysis of stability, prognostic factors and survival Radiat Oncol 2014 9 194 10.1186/1748-717X-9-194Open DOISearch in Google Scholar

5Rief H, Bischof M, Bruckner T, Welzel T, Askoxylakis V, Rieken S, et al. The stability of osseous metastases of the spine in lung cancer - a retrospective analysis of 338 cases. Radiat Oncol 2013; 8: 200. 10.1186/1748-717X-8-200RiefHBischofMBrucknerTWelzelTAskoxylakisVRiekenS The stability of osseous metastases of the spine in lung cancer - a retrospective analysis of 338 cases Radiat Oncol 2013 8 200 10.1186/1748-717X-8-200Open DOISearch in Google Scholar

6Schlampp I, Rieken S, Habermehl D, Bruckner T, Förster R, Debus J, et al. Stability of spinal bone metastases in breast cancer after radiotherapy: a retrospective analysis of 157 cases. Strahlenther Onkol 2014; 190: 792-7. 10.1007/s00066-014-0651-zSchlamppIRiekenSHabermehlDBrucknerT FörsterRDebusJ Stability of spinal bone metastases in breast cancer after radiotherapy: a retrospective analysis of 157 cases Strahlenther Onkol 2014 190 7927 10.1007/s00066-014-0651-zOpen DOISearch in Google Scholar

7Foerster R, Eisele C, Bruckner T, Bostel T, Schlampp I, Wolf R, et al. Bone density as a marker for local response to radiotherapy of spinal bone metastases in women with breast cancer: a retrospective analysis. Radiat Oncol 2015; 10: 62. 10.1186/s13014-015-0368-xFoersterREiseleCBrucknerTBostelTSchlamppIWolfR Bone density as a marker for local response to radiotherapy of spinal bone metastases in women with breast cancer: a retrospective analysis Radiat Oncol 2015 10 62 10.1186/s13014-015-0368-xOpen DOISearch in Google Scholar

8Rief H, Petersen LC, Omlor G, Akbar M, Bruckner T, Rieken S, et al. The effect of resistance training during radiotherapy on spinal bone metastases in cancer patients - a randomized trial. Radiother Oncol 2014; 112: 133-9. 0.1016/j.radonc.2014.06.008RiefHPetersenLCOmlorGAkbarMBrucknerTRiekenS The effect of resistance training during radiotherapy on spinal bone metastases in cancer patients - a randomized trial Radiother Oncol 2014 112 1339 0.1016/j.radonc.2014.06.008Open DOISearch in Google Scholar

9Bostel T, Förster R, Schlampp I, Wolf R, Serras AF, Mayer A, et al. Stability, prognostic factors and survival of spinal bone metastases in malignant melanoma patients after palliative radiotherapy. Tumori 2016; 102: 156-61. 10.5301/tj.5000382BostelTFörsterRSchlamppIWolfRSerrasAFMayerA Stability, prognostic factors and survival of spinal bone metastases in malignant melanoma patients after palliative radiotherapy Tumori 2016 102 15661 10.5301/tj.5000382Open DOISearch in Google Scholar

10Schlampp I, Lang H, Förster R, Wolf R, Bostel T, Bruckner T, et al. Stability of spinal bone metastases and survival analysis in renal cancer after radiotherapy. Tumori 2015; 101: 614-20. 10.5301/tj.5000370SchlamppILangHFörsterRWolfRBostelTBrucknerT Stability of spinal bone metastases and survival analysis in renal cancer after radiotherapy Tumori 2015 101 61420 10.5301/tj.5000370Open DOISearch in Google Scholar

11Abe T, Shinohara N, Harabayashi T, Sazawa A, Maruyama S, Suzuki S, et al. Impact of multimodal treatment on survival in patients with metastatic urothelial cancer. Eur Urol 2007; 52: 1106-13. 10.1016/j.eururo.2007.02.052AbeTShinoharaNHarabayashiTSazawaAMaruyamaSSuzukiS Impact of multimodal treatment on survival in patients with metastatic urothelial cancer Eur Urol 2007 52 110613 10.1016/j.eururo.2007.02.052Open DOISearch in Google Scholar

12Bellmunt J, Albanell J, Paz-Ares L, Climent MA, Gonzalez-Larriba JL, Carles J, et al. Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin, and gemcitabine. Cancer 2002; 95: 751-7. 10.1002/cncr.10762BellmuntJAlbanellJPaz-AresLClimentMAGonzalez-LarribaJLCarlesJ Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin, and gemcitabine Cancer 2002 95 7517 10.1002/cncr.10762Open DOISearch in Google Scholar

13Saxman SB, Propert KJ, Einhorn LH, Crawford ED, Tannock I, Raghavan D, et al. Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 1997; 15: 2564-9. 10.1200/jco.1997.15.7.2564SaxmanSBPropertKJEinhornLHCrawfordEDTannockIRaghavanD Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study J Clin Oncol 1997 15 25649 10.1200/jco.1997.15.7.2564Open DOISearch in Google Scholar

14Habermehl D, Haase K, Rieken S, Debus J, Combs SE. Defining the role of palliative radiotherapy in bone metastasis from primary liver cancer: an analysis of survival and treatment efficacy. Tumori 2011; 97: 609-13. 10.1700/989.10720HabermehlDHaaseKRiekenSDebusJCombsSE. Defining the role of palliative radiotherapy in bone metastasis from primary liver cancer: an analysis of survival and treatment efficacy Tumori 2011 97 60913 10.1700/989.10720Open DOISearch in Google Scholar

15Rief H, Heinhold M, Bruckner T, Schlampp I, Forster R, Welzel T, et al. Quality of life, fatigue and local response of patients with unstable spinal bone metastases under radiation therapy--a prospective trial. Radiat Oncol 2014; 9: 133. 10.1186/1748-717X-9-133RiefHHeinholdMBrucknerTSchlamppIForsterRWelzelT Quality of life, fatigue and local response of patients with unstable spinal bone metastases under radiation therapy--a prospective trial Radiat Oncol 2014 9 133 10.1186/1748-717X-9-133Open DOISearch in Google Scholar

16Chow R, Hoskin P, Chan S, Mesci A, Hollenberg D, Lam H, et al. Efficacy of multiple fraction conventional radiation therapy for painful uncomplicated bone metastases: A systematic review. Radiother Oncol 2017; 122: 323-31. 10.1016/j.radonc.2016.12.031ChowRHoskinPChanSMesciAHollenbergDLamH Efficacy of multiple fraction conventional radiation therapy for painful uncomplicated bone metastases: A systematic review Radiother Oncol 2017 122 32331 10.1016/j.radonc.2016.12.031Open DOISearch in Google Scholar

17Zaghloul MS, Boutrus R, El-Hossieny H, Kader YA, El-Attar I, Nazmy M. A prospective, randomized, placebo-controlled trial of zoledronic acid in bony metastatic bladder cancer. Int J Clin Oncol 2010; 15: 382-9. 10.1007/s10147-010-0074-5ZaghloulMSBoutrusREl-HossienyHKaderYAEl-AttarINazmyM. A prospective, randomized, placebo-controlled trial of zoledronic acid in bony metastatic bladder cancer Int J Clin Oncol 2010 15 3829 10.1007/s10147-010-0074-5Open DOISearch in Google Scholar